Ablynx is a pioneer in the discovery and development of a novel class of therapeutic proteins known as Nanobodies®. The structure and extreme stability of Nanobodies® enables them to engage therapeutic targets that are inaccessible to conventional antibodies. Nanobodies® therefore address the strong and growing demand for improved therapeutics for serious and life-threatening diseases, and have the potential to create new market opportunities beyond those accessible to conventional antibodies.
Since commencing operations in 2002, Ablynx has generated Nanobody® leads against a number of human disease targets across a wide range of therapeutic areas. Two of these leads are now in advanced pre-clinical development, and Ablynx’s first therapeutic program is expected to enter human clinical trials in 2006.
Ablynx’s Nanobody® technology was originally discovered at laboratories of the Free University of Brussels (VUB). Scientists at the VUB discovered that up to half of the antibody repertoire in camelidae consists of antibodies that lack a conventional antibody light-chain, but retain full antigen-binding capacity. The technology and intellectual property created around this discovery was further developed within the Flanders Interuniversity Institute for Biotechnology (VIB). In 2001 VIB created Ablynx in collaboration with founding venture investor, GIMV. Ablynx now operates from its state-of-the-art facilities in Ghent, Belgium.
Dr. Jeffrey Dick
In this interview conducted at Pittcon 2023 in Philadelphia, Pennsylvania, we spoke to Dr. Jeffrey Dick about his work studying the chemistry of small volumes and nano-electrochemical tools.
Here, AZoNano speaks with Dirigent Acoustics about the benefits graphene could bring to acoustic and audio technologies and how the company's relationship with the Graphene Flagship has shaped its success.
In this interview, KLA's Bryan Crawford explains everything there is to know about nanoindentation, the challenges that the field currently faces, and how they can be overcome.
The Diamond Interaction Chamber (DIXC) is integral to the NanoGenizer high-pressure homogenizer.
The new AUTOsample-100 mounting autosampler is compatible with the 100 MHz benchtop NMR spectrometer.
The Vistec SB3050-2 is the most advanced electron beam lithography system with variable-shaped beam technology, allowing a wide range of applications in research and development, prototyping, and small-volume production.